Your search found 1 Results
London, England, IPPF, April 1983. 9 p. (IPPF Fact Sheet)Discusses the International Planned Parenthood Federation's (IPPF) position on the use of injectable contraceptives. The 2 currently available injectable contraceptives are depot medroxyprogesterone acetate (DMPA), which is marketed under the name Depo-Provera, and norethisterone acetate (NET-EN), sold as Noristerat or Norigest. Injectable contraceptives are highly effective, convenient, and have a long-acting effect which is an advantage. DMPA has been approved for contraceptive use in more than 80 developing and developed countries, and NEP-EN, a recent introduction, in 40 countries. After the contraceptive has been approved for domestic use, it is supplied by IPPF to those countries which request it. Injectables are also provided for contraceptive use by the World Health Organization (WHO) and the United Nations Fund for Population Activities (UNFPA). The current positions of the WHO and the IPPF are covered, as well as the positions of Britain, Sweden, and the United States. Criticisms of the injectable contraceptives and IPPF's position regarding these are also discussed. After taking the criticisms into account, IPPF concludes that there is not sufficient reason to change its current position on injectable contraceptives. It will continue to keep all methods under close and continuous review.